Table 3.
The differences of parameters between patients of MSA-C and SCA with different disease durations.
| The differences of parameters between patients with MSA-C and SCA with a disease duration within 1 year | |||||
|---|---|---|---|---|---|
| Total (N = 132) | SCA (N = 47) | MSA-C (N = 85) | p value | ||
| HCBSb | Positive | 1 (2.13%) | 70 (82.35%) | 0.000 | |
| Negative | 46 (97.87%) | 15 (17.65%) | |||
| Disease durationa | 0.91 ± 0.28 | 0.87 ± 0.34 | 0.94 ± 0.24 | 0.264 | |
| Cerebelluma | NAA/Cr | 0.76 ± 0.18 | 0.94 ± 0.14 | 0.66 ± 0.12 | 0.000 |
| Cho/Cr | 0.65 ± 0.15 | 0.74 ± 0.17 | 0.60 ± 0.10 | 0.000 | |
| Vermisa | NAA/Cr | 0.78 ± 0.10 | 0.86 ± 0.09 | 0.73 ± 0.08 | 0.000 |
| Cho/Cr | 0.64 ± 0.09 | 0.69 ± 0.09 | 0.61 ± 0.07 | 0.000 | |
| SARA scorea | Total (N = 111) | SCA (N = 42) | MSA-C (N = 69) | 0.000 | |
| 9.48 ± 5.32 | 6.40 ± 4.22 | 11.19 ± 5.11 | |||
| The differences of parameters between patients with MSA-C and SCA with a disease duration in the bracket of 2–3 years | |||||
|---|---|---|---|---|---|
| Total (N = 191) | SCA (N = 89) | MSA-C (N = 102) | |||
| HCBSb | Positive | 8 (8.99%) | 95 (93.14%) | 0.000 | |
| Negative | 81 (91.01%) | 7 (6.86%) | |||
| Disease durationa | 2.51 ± 0.50 | 2.57 ± 0.50 | 2.46 ± 0.50 | 0.120 | |
| Cerebelluma | NAA/Cr | 0.76 ± 0.19 | 0.88 ± 0.19 | 0.65 ± 0.11 | 0.000 |
| Cho/Cr | 0.64 ± 0.13 | 0.70 ± 0.13 | 0.59 ± 0.10 | 0.000 | |
| Vermisa | NAA/Cr | 0.75 ± 0.11 | 0.81 ± 0.11 | 0.73 ± 0.08 | 0.000 |
| Cho/Cr | 0.64 ± 0.10 | 0.69 ± 0.10 | 0.60 ± 0.08 | 0.000 | |
| SARA scorea | Total (N = 163) | SCA (N = 76) | MSA-C (N = 87) | 0.000 | |
| 11.86 ± 6.47 | 8.49 ± 5.70 | 14.76 ± 5.66 | |||
| The differences of parameters between patients with MSA-C and SCA with a disease duration in the bracket of 4–5 years | |||||
|---|---|---|---|---|---|
| Total (N = 160) | SCA (N = 61) | MSA-C (N = 99) | |||
| HCBSb | Positive | 3 (4.92%) | 96 (96.97%) | 0.000 | |
| Negative | 58 (95.08%) | 3 (3.03%) | |||
| Disease durationa | 4.49 ± 0.51 | 4.62 ± 0.49 | 4.41 ± 0.50 | 0.009 | |
| Cerebelluma | NAA/Cr | 0.69 ± 0.1863 + | 0.85 ± 0.15 | 0.59 ± 0.11 | 0.000 |
| Cho/Cr | 0.60 ± 0.14 | 0.68 ± 0.11 | 0.54 ± 0.13 | 0.000 | |
| Vermisa | NAA/Cr | 0.71 ± 0.13 | 0.82 ± 0.09 | 0.64 ± 0.10 | 0.000 |
| Cho/Cr | 0.61 ± 0.11 | 0.69 ± 0.08 | 0.57 ± 0.09 | 0.000 | |
| SARA scorea | Total (N = 134) | SCA (N = 53) | MSA-C (N = 81) | 0.000 | |
| 16.43 ± 7.06 | 11.61 ± 4.07 | 19.52 ± 6.84 | |||
| The differences of parameters between patients with MSA-C and SCA with a disease duration in the bracket of 6–8 years | |||||
|---|---|---|---|---|---|
| Total (N = 151) | SCA (N = 88) | MSA-C (N = 63) | |||
| HCBSb | Positive | 11 (12.50%) | 61 (96.83%) | 0.000 | |
| Negative | 77 (87.50%) | 2 (3.17%) | |||
| Disease durationa | 6.77 ± 0.78 | 6.69 ± 0.76 | 6.87 ± 0.81 | 0.159 | |
| Cerebelluma | NAA/Cr | 0.72 ± 0.21 | 0.83 ± 0.18 | 0.56 ± 0.13 | 0.000 |
| Cho/Cr | 0.60 ± 0.15 | 0.68 ± 0.11 | 0.48 ± 0.11 | 0.000 | |
| Vermisa | NAA/Cr | 0.73 ± 0.13 | 0.81 ± 0.09 | 0.62 ± 0.09 | 0.000 |
| Cho/Cr | 0.61 ± 0.13 | 0.68 ± 0.10 | 0.52 ± 0.10 | 0.000 | |
| SARA scorea | Total (N = 132) | SCA (N = 80) | MSA-C (N = 52) | 0.000 | |
| 16.50 ± 8.44 | 11.99 ± 5.50 | 22.99 ± 7.70 | |||
| The differences of parameters between patients with MSA-C and SCA with a disease duration longer than 8 years | |||||
|---|---|---|---|---|---|
| Total (N = 157) | SCA (N = 127) | MSA-C (N = 30) | |||
| HCBSb | Positive | 13 (10.24%) | 29 (96.67%) | 0.000 | |
| Negative | 114 (89.76%) | 1 (3.33%) | |||
| Disease durationa | 12.50 ± 4.94 | 13.24 ± 5.17 | 9.38 ± 1.60 | 0.000 | |
| Cerebelluma | NAA/Cr | 0.74 ± 0.17 | 0.78 ± 0.15 | 0.54 ± 0.12 | 0.000 |
| Cho/Cr | 0.62 ± 0.13 | 0.65 ± 0.11 | 0.47 ± 0.11 | 0.000 | |
| Vermisa | NAA/Cr | 0.74 ± 0.14 | 0.76 ± 0.13 | 0.63 ± 0.10 | 0.000 |
| Cho/Cr | 0.62 ± 0.11 | 0.65 ± 0.10 | 0.52 ± 0.09 | 0.000 | |
| SARA scorea | Total (N = 128) | SCA (N = 103) | MSA-C (N = 25) | 0.000 | |
| 17.96 ± 8.95 | 16.20 ± 8.25 | 25.20 ± 8.20 | |||
aMann-Whitney test. bChi-square test.
Numeric data are presented as mean ± standard deviation.
HCBS hot cross bun sign; MSA-C multiple system atrophy, cerebellar type; SCA spinocerebellar ataxia; SARA Scale for the Assessment and Rating of Ataxia; NAA N-acetyl aspartate; Cr creatinine; Cho Choline.